Cognition Therapeutics (CGTX) Accounts Payables (2020 - 2026)

Cognition Therapeutics (CGTX) has 7 years of Accounts Payables data on file, last reported at $3.8 million in Q1 2026.

• Quarterly Accounts Payables rose 111.42% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (up 111.42% YoY) and the FY2025 annual result came in at $1.1 million, down 43.6% from the prior year.
• Accounts Payables rose to $3.8 million in Q1 2026 per CGTX's latest filing, from $1.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $8.1 million in Q3 2022 and bottomed at $771000.0 in Q2 2025.
• The 5-year median for Accounts Payables is $3.0 million (2024), against an average of $3.0 million.
• The widest annual swing landed in 2022, when Accounts Payables surged 191.42%; it then sank 74.59% in 2025.
• Tracing CGTX's Accounts Payables over 5 years: stood at $3.2 million in 2022, then advanced by 14.89% to $3.7 million in 2023, then plunged by 46.31% to $2.0 million in 2024, then slumped by 43.6% to $1.1 million in 2025, then soared by 244.06% to $3.8 million in 2026.
• Per Business Quant, the three latest CGTX Accounts Payables figures stand at $3.8 million (Q1 2026), $1.1 million (Q4 2025), and $827000.0 (Q3 2025).

Peer Comparison